Evolution of treatment practices and outcomes in multiple myeloma during 2013–2022: a Finnish real world registry study
DOI:
https://doi.org/10.2340/1651-226X.2025.42647Keywords:
real-world data, Multiple myeloma, outcome, survival, treatment, novel therapyAbstract
Background and purpose: Multiple myeloma (MM) is a heterogenous hematologic malignancy with an evolving treatment landscape. This Finnish real-world evidence study clarifies the evolution of treatment practices and outcomes over recent years.
Methods: This retrospective analysis included 1,733 patients with MM diagnosed between 2013 and 2022. The cohort was identified and electronic health record data were collected from four hospital data lakes and linked to national registries, covering 54% of Finland’s population. Patients were divided by stem cell transplantation (SCT) status into a SCT group (512 patients) and a non-SCT group (1,221 patients), and further by diagnosis period (2013–2017 vs. 2018–2022).
Results: The average age of the patients was 71.3 years at diagnosis. Novel therapeutic use markedly increased during the follow-up, especially lenalidomide as part of frontline and maintenance therapy in SCT patients. For SCT patients the 4-year survival rate improved from 81.7% (95% confidence interval [CI]: 76.4–86.0) in 2013–2017 to 93.0% (95% CI: 87.0–96.3) in 2018–2022. For non-SCT-patients, the median overall survival (OS) increased slightly from 41.3 months (95% CI: 38.1–45.6) in the 2013–2017 period to 43.8 months (95% CI: 39.8–55.3) in the 2018–2022 period, although the difference was not statistically significant. High risk cytogenetics and high International Staging System class appeared to persist as factors indicating shorter OS.
Interpretation: While advancements of novel drugs have resulted in a notable survival benefit for patients undergoing SCT, the survival of non-SCT-patients has remained comparatively static. New approaches in the treatment of MM for elderly and frail non-SCT patients are warranted.
Downloads
References
Cancer Registry, Finland. Syöpärekisteri. Cancer statistics [Internet]. [cited 2023 May 22]. Available from: https://cancerregistry.fi/statistics/cancer-statistics/
Morè S, Corvatta L, Manieri VM, Morsia E, Poloni A, Offidani M. Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment. Pharmaceuticals. 2023;16(11):1628.
https://doi.org/10.3390/ph16111628 DOI: https://doi.org/10.3390/ph16111628
Hagiwara M, Panjabi S, Delea T, Yucel E, Fonseca R. Burden of disease progression in patients with multiple myeloma in the US. Leuk Lymphoma. 2020;61(1):47–55.
https://doi.org/10.1080/10428194.2019.1648802 DOI: https://doi.org/10.1080/10428194.2019.1648802
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(3):309–22.
https://doi.org/10.1016/j.annonc.2020.11.014 DOI: https://doi.org/10.1016/j.annonc.2020.11.014
Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16(1):11–20.
https://doi.org/10.6004/jnccn.2018.0002 DOI: https://doi.org/10.6004/jnccn.2018.0002
Finnish Myeloma Group. Suomen hematologiyhdistys. National treatment guideline 2024 [Internet]. [cited 2024 Sept 24]. Available from: https://hematology.fi/hoito-ohjeet/hoito-ohje-1/plasmasolutaudit/myelooma/hoito/kansallinen-hoitosuositus-fmg/
Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.
https://doi.org/10.1016/j.clml.2019.09.621 DOI: https://doi.org/10.1016/j.clml.2019.09.621
Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, et al. Long-term outcomes in patients with multiple myeloma. HemaSphere. 2018;2(4):e45.
https://doi.org/10.1097/HS9.0000000000000045 DOI: https://doi.org/10.1097/HS9.0000000000000045
Vikkula J, Uusi-Rauva K, Ranki T, Toppila I, Aalto-Setälä M, Pousar K, et al. Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland. Future Oncol. 2023;19(30):2029–43.
https://doi.org/10.2217/fon-2023-0120 DOI: https://doi.org/10.2217/fon-2023-0120
Tskhvarashvili G, Hakkarainen KM, Klement R, Vattulainen P, Miettinen T, Lievonen J. Descriptive analysis of multiple myeloma patients in a real-world setting from the Finnish Hematology Registry. Int J Clin Exp Med. 2024;17(2):19–30.
https://doi.org/10.62347/IFUW3775 DOI: https://doi.org/10.62347/IFUW3775
Loponen H, Mehtälä J, Ylisaukko‐oja T, Brück O, Porkka K, Koskenvesa P, et al. Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland. EJHaem. 2023;4(4):1019–29.
https://doi.org/10.1002/jha2.802 DOI: https://doi.org/10.1002/jha2.802
Ruotsalainen J, Lehmus L, Putkonen M, Lievonen J, Kallio A, Raittinen P, et al. Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study. Ann Hematol. 2024;103(4):1273–84.
https://doi.org/10.1007/s00277-023-05571-1 DOI: https://doi.org/10.1007/s00277-023-05571-1
Toppila I, Miettinen T, Lassenius MI, Lievonen J, Bauer M, Anttila P. Characteristics and survival trends in Finnish multiple myeloma patients – a nationwide real-world evidence study. Ann Hematol. 2021;100(7):1779–87.
https://doi.org/10.1007/s00277-021-04481-4 DOI: https://doi.org/10.1007/s00277-021-04481-4
Kysenius K, Anttalainen A, Toppila I, Miettinen T, Lassenius M, Lievonen J, et al. Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021. Ann Hematol. 2024;103(8):2931–43.
https://doi.org/10.1007/s00277-024-05865-y DOI: https://doi.org/10.1007/s00277-024-05865-y
Kosunen M, Ruotsalainen J, Kallio A, Metsä R, Raittinen P, Lehmus L, et al. Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: a nationwide cohort study of patients with multiple myeloma in Finland. Pharmacoecon Open. 2025;9(1):57–68.
https://doi.org/10.1007/s41669-024-00524-4 DOI: https://doi.org/10.1007/s41669-024-00524-4
Martínez-Lopez J, Bailey A, Lambert A, Luke E, Ribbands A, Erler-Yates N, et al. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 2023;19(31):2103–21.
https://doi.org/10.2217/fon-2023-0021 DOI: https://doi.org/10.2217/fon-2023-0021
Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, et al. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer J. 2023;13(1):181.
https://doi.org/10.1038/s41408-023-00946-z DOI: https://doi.org/10.1038/s41408-023-00946-z
Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103(3):506–13.
https://doi.org/10.3324/haematol.2017.178103 DOI: https://doi.org/10.3324/haematol.2017.178103
Leleu X, Gorsh B, Bessou A, Paka P, De Nascimento J, Colin X, et al. Survival outcomes for patients with multiple myeloma in France: a retrospective cohort study using the Système National des Données de Santé national healthcare database. Eur J Haematol. 2023;111(1):125–34.
https://doi.org/10.1111/ejh.13976 DOI: https://doi.org/10.1111/ejh.13976
Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126(7):921–2.
https://doi.org/10.1182/blood-2015-05-647636 DOI: https://doi.org/10.1182/blood-2015-05-647636
Luoma S, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen T, et al. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. Ann Hematol. 2019;98(12):2781–92.
https://doi.org/10.1007/s00277-019-03815-7 DOI: https://doi.org/10.1007/s00277-019-03815-7
Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Säily M, et al. Ixazomib, lenalidomide, and dexamethasone (IRD) treatment with cytogenetic risk-based maintenance in transplant-eligible myeloma: a phase 2 multicenter study by the Nordic Myeloma Study Group. Cancers. 2024;16(5):1024.
https://doi.org/10.3390/cancers16051024 DOI: https://doi.org/10.3390/cancers16051024
Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, et al. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer J. 2023;13(1):1–10.
https://doi.org/10.1038/s41408-023-00905-8 DOI: https://doi.org/10.1038/s41408-023-00905-8
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Anu Partanen, Marika Waltari, Johanna Vikkula, Riikka Mattila, Katja Närhi, Jonna Eeva, Mervi Putkonen
This work is licensed under a Creative Commons Attribution 4.0 International License.
